Moreover, a study by Pan and colleagues investigated development of a potent anti-tumor vaccine co-loaded with stearic acid-doped lipid nanoparticles (sLNPs), OVA-encoding mRNA, and a TLR4 agonist, monophosphoryl lipid A (MPLA) [80]. This evidence concerns the gene TLR4 and neoplasm.